explore -WSS

explore

author：knowledge 2025-09-30 22:05:37 - browse：4

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Bird flu outbreak in cows is latest avian flu curveball

hotspot

WSS

Steward Health Care files for bankruptcy

Hospital chaplains balance Covid safety with patients’ spiritual needs

Brain worms: The science behind RFK Jr.'s parasitic infection

Medicare Advantage coverage denials need scrutiny, senators say

Profiling embryos to choose those with higher IQs is almost a reality

Use wet bulb globe temperature, not heat index, to protect workers

focus

explore

entertainment

Medicare details structure of new drug price negotiation program

A preacher's new calling: Diversifying neuroscience research

New air purifier tech could be key to improving indoor air quality

A preacher's new calling: Diversifying neuroscience research

In Memoriam: Notable people who died in 2023

Boston Scientific acquires urology company Axonics for $3.7 billion

New air purifier tech could be key to improving indoor air quality

Arena BioWorks launches in Cambridge to speed drug discovery

Wildfire smoke exposes gaps in outdoor worker protections

In shift, Texas to cover initial consult for Afghan baby's gene therapy

knowledge

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Researchers on aging grapple with how to calculate biological age

At JPM 2024, hospital systems pitch financial strength to investors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Wikipedia

explore

hotspot

entertainment